ArticleCancer medicine2026
Exosomal miR-4644 Targets SPRY3 to Promote Proliferation and Invasion of Pancreatic Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTumor-derived exosomes (TDEs) can carry diverse genetic material that modulates pancreatic cancer (PC) proliferation and invasion. Despite this, the involvement of microRNAs (miRNAs) in TDE-mediated tumor progression in PC remains inadequately explored.
methodsUltracentrifugation was used to isolate exosomes derived from AsPC-1 and BxPC-3 cells. Cell proliferation was assessed by cell counting kit-8 (CCK-8) and plate colony formation assays. Cell migration and invasion were evaluated using Transwell assays. Real-time polymerase chain reaction (RT-PCR) was performed to detect the expression levels of miR-4644 and Sprouty RTK Signaling Antagonist 3 (SPRY3). A dual-luciferase reporter assay was conducted to verify the binding site between miR-4644 and SPRY3. Orthotopic PC xenografts were established to validate the effects of SPRY3 and miR-4644. Finally, the relative expression levels of SPRY3 were validated using PC tissue and matched adjacent non-tumor tissue samples.
resultsMiR-4644 was enriched in TDEs, and the inhibition of miR-4644 reduced the proliferation, migration, and invasion of PC cells. SPRY3 was identified as a direct target of miR-4644, which bound to the 3'-UTR of SPRY3 and suppressed its expression. The inhibitory effects of SPRY3 on PC cell proliferation, migration, and invasion were partially counteracted by miR-4644. Importantly, clinical data analysis revealed that SPRY3 expression was significantly downregulated in PC tissues (p < 0.05). Mechanistically, miR-4644 targeted SPRY3 and promoted PC cell proliferation, migration, and invasion through the Ras-Raf-MAPK signaling pathway.
conclusionsMiR-4644 is upregulated in PC TDEs and promotes PC cell progression by suppressing SPRY3 expression; high expression of exosomal miR-4644 correlates with poor patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.